Triple
T23186862
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | VelocImmune technology |
E579613
|
entity |
| Predicate | componentOf |
P35
|
FINISHED |
| Object | Regeneron antibody discovery and development platform |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Regeneron antibody discovery and development platform | Statement: [VelocImmune technology, componentOf, Regeneron antibody discovery and development platform]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Regeneron antibody discovery and development platform Context triple: [VelocImmune technology, componentOf, Regeneron antibody discovery and development platform]
-
A.
Regeneron Pharmaceuticals
chosen
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
B.
REGN-COV2
REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
-
C.
VelocImmune technology
VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
-
D.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
E.
mosunetuzumab (bispecific antibody component)
Mosunetuzumab is a bispecific monoclonal antibody that redirects T cells to attack CD20-expressing B cells, used in the treatment of certain B-cell malignancies.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e245ff8000819090d12008805315b7 |
completed | April 17, 2026, 2:38 p.m. |
| NER | Named-entity recognition | batch_69f18fd3aaa08190b9cf7afe4ee5a38d |
completed | April 29, 2026, 4:57 a.m. |
Created at: April 17, 2026, 4:05 p.m.